Of Cells and Limits

Leonard Hayflick has been unafraid to speak his mind, whether it is to upend a well-entrenched dogma or to challenge the federal government. At 86, he’s nowhere near retirement.

Written byAnna Azvolinsky
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

LEONARD HAYFLICK
Adjunct Professor of Anatomy
University of California, San Francisco
© RAMIN RAHIMIAN
Leonard Hayflick learned to culture cells under the tutelage of a famous expert, Charles Pomerat. In 1958, after completing his fellowship in Pomerat’s lab, Hayflick became a member of the Wistar Institute in Philadelphia, providing cell cultures for its researchers. “It was a golden opportunity because it would leave me with plenty of time and resources to do what I wanted to do without worrying about getting grants or being subject to supervision.”

Hayflick was interested in detecting viruses that might cause human cancer. He would extract viruses from the culture fluid in which he grew cancer cells and attempt to transform normal cells into tumor cells. Human adult cells frequently contained unwanted viruses, so Hayflick obtained tissue from fetuses to use as a source of virus-free normal cells. He found that tissue from the lung, which is already a discrete organ by three months of embryonic development, was best for making fibroblast cell strains. “Like everyone else who did cell culture, I was persuaded to believe the 60-year-old dogma that when you culture cells, they have the capacity to divide forever. In practice, this never happened and people attributed their failure to ignorance of culturing methods, media ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies